Jan 17 (Reuters) - PHARMING GROUP NV:
* PHARMING ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS
* ‍FDA INDICATED SBLA IS SUFFICIENTLY COMPLETE TO PERMIT SUBSTANTIVE REVIEW
* ‍FDA SET AN ACTION DATE OF SEPTEMBER 21, 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)
 